title: Evaluation of stability of allergen extracts for sublingual immunotherapy during transport under unfavourable temperature conditions with an innovative thermal insulating packaging.
abstract: Many pharmaceutical and biotechnological products are temperature-sensitive and should normally be kept at a controlled temperature, particularly during transport, in order to prevent the loss of their stability and activity. Therefore, stability studies should be performed for temperature-sensitive products, considering product characteristics, typical environmental conditions, and anticipating environmental extremes that may occur during product transport in a specific country. Staloral products for sublingual immunotherapy are temperature sensitive and are labelled for maintenance under refrigerated conditions (2-8°C). Given the peculiar climatic context of Italy and the great temperature fluctuations that may occur during transport, this study was aimed at evaluating the impact of a new engineered thermal insulating packaging for Staloral. In particular, the purpose was to assess whether the new packaging could create a container condition able to preserve the stability and immunological activity of the product during the transport phase throughout Italy. The results showed that the range of temperatures that can affect the product, in the area surrounding the product packaging, may reach a peak of 63°C during transport under the most unfavourable climatic conditions, i.e. in a non-refrigerated van during the summer season, from the site of production in France to the patient's house in Catania, the city with the highest temperatures in Italy. However, the highest temperature reached inside the vaccine did not exceed 45°C over a period of about 2 h. The ELISA inhibition test on samples subjected to the extreme temperature conditions previously defined (45°C) showed an immunological activity higher than 75% of that initially measured and was comparable to those obtained with samples stored at controlled temperature (5°C). This means that, even in the worst case scenario, the structure of the allergen extracts is not influenced and the vaccine potency is preserved.
authors.affiliation: . vnatoli@stallergenes.it.
authors.forename: P
authors.initials: P
authors.lastname: Puccinelli
authors.forename: V
authors.initials: V
authors.lastname: Natoli
authors.forename: I
authors.initials: I
authors.lastname: Dell'albani
authors.forename: S
authors.initials: S
authors.lastname: Scurati
authors.forename: C
authors.initials: C
authors.lastname: Incorvaia
authors.forename: S
authors.initials: S
authors.lastname: Barbieri
authors.forename: S
authors.initials: S
authors.lastname: Masieri
authors.forename: F
authors.initials: F
authors.lastname: Frati
mesh_terms: D000485:Allergens / Q000737:chemistry*; D004349:Drug Packaging; D004355:Drug Stability; D006801:Humans; D063729:Sublingual Immunotherapy; D013696:Temperature; D014186:Transportation; D014612:Vaccines / Q000737:chemistry
chemical_list: D000485:Allergens; D014612:Vaccines